Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1634 1646 1674
This examiner grants 59% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 19333264 | Stabilized Formulations Containing Anti-Interleukin-4 Receptor (IL-4R) Antibodies | Final Rejection | Regeneron Pharmaceuticals, Inc. |
| 18359483 | PROTEIN BINDING DOMAINS STABILIZING FUNCTIONAL CONFORMATIONAL STATES OF GPCRS AND USES THEREOF | Non-Final OA | The Board of Trustees of the Leland Stanford Junior University |
| 17924612 | COMPOSITIONS AND METHODS FOR TREATING LYSOSOMAL STORAGE DISORDERS | Non-Final OA | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY |
| 19055378 | METHODS OF ENHANCING EFFICACY OF IMMUNOCONJUGATES USING PAIRED HUMAN ANTIBODIES TARGETED AT NON-OVERLAPPING B-CELL EPITOPES ON THE SAME ANTIGEN | Final Rejection | Medicovestor, Inc. |
| 18333172 | COMPOSITIONS AND METHODS FOR TARGETED CYTOKINE DELIVERY | Non-Final OA | Washington University |
| 17905453 | USE OF ANTI-FAM19A1 ANTAGONISTS FOR TREATING CENTRAL NERVOUS SYSTEM DISEASES | Non-Final OA | NEURACLE SCIENCE CO., LTD. |
| 17716467 | ANTIGEN-BINDING MOLECULE FOR PROMOTING CLEARANCE FROM PLASMA OF ANTIGEN COMPRISING SUGAR CHAIN RECEPTOR-BINDING DOMAIN | Final Rejection | Chugai Seiyaku Kabushiki Kaisha |
| 18052476 | SERINE PROTEASE MOLECULES AND THERAPIES | Final Rejection | Research Development Foundation |
| 17487164 | NANOPORES WITH INTERNAL PROTEIN ADAPTORS | Final Rejection | Rijksuniversiteit Groningen |
| 18304801 | MUTANT G-PROTEIN COUPLED RECEPTORS AND METHODS FOR SELECTING THEM | Final Rejection | NXERA PHARMA UK LIMITED |
| 17915567 | RNA COMPOSITIONS TARGETING CLAUDIN-18.2 | Non-Final OA | BioNTech SE |
| 18253756 | ANTI-GALECTIN-9 ANTIBODIES AND THERAPEUTIC USES THEREOF | Non-Final OA | PureTech LYT, Inc. |
| 18000010 | METHODS AND COMPOSITIONS FOR TREATING, PREVENTING THE ONSET AND/OR SLOWING PROGRESSION OF OSTEOARTHRITIS | Non-Final OA | New York Society for the Relief of the Ruptured and Crippled, maintaining the Hospital for Special |
| 17596140 | Genetically Engineered Cells Sensitive for Clostridial Neurotoxins | Non-Final OA | SYNAPTIC RESEARCH, LLC |
| 17514898 | NEUROPILIN ANTIBODY NASAL SPRAY TO REDUCE COVID-19 TRANSMISSION | Final Rejection | MARV ENTERPRISES LLC |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy